Cargando…

Platelet sensitivity to prostacyclin in normal subjects, and in patients with benign and malignant tumours of the breast.

Platelet sensitivity to prostacyclin (PG12) was determined in normal male and female subjects, and in patients with benign and malignant tumours of the breast. The IC50 overall mean values for PG12 on ADP-induced platelet aggregation were similar for normal men and women, being 0.97 +/- 0.05 ng ml-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Benedetto, C., Zonca, M., Tavella, A. M., Petitti, E., Massobrio, M., Nigam, S., Slater, T. F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1985
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976827/
https://www.ncbi.nlm.nih.gov/pubmed/3881119
_version_ 1782135135720701952
author Benedetto, C.
Zonca, M.
Tavella, A. M.
Petitti, E.
Massobrio, M.
Nigam, S.
Slater, T. F.
author_facet Benedetto, C.
Zonca, M.
Tavella, A. M.
Petitti, E.
Massobrio, M.
Nigam, S.
Slater, T. F.
author_sort Benedetto, C.
collection PubMed
description Platelet sensitivity to prostacyclin (PG12) was determined in normal male and female subjects, and in patients with benign and malignant tumours of the breast. The IC50 overall mean values for PG12 on ADP-induced platelet aggregation were similar for normal men and women, being 0.97 +/- 0.05 ng ml-1 and 0.83 +/- 0.07 ng ml-1 respectively. However, there were significant differences in the IC50 values for women in the 1st (0.81 +/- 0.06 ng ml-1) vs. 2nd (1.37 +/- 0.13 ng ml-1) phase of the menstrual cycle; post-menopausal women gave similar values to normal males and to pre-menopausal women in the 1st phase of the cycle. No significant differences were found between normal subjects and patients with benign or malignant tumours of the breast when account was taken of the status of the patient in relation to the phase of the menstrual cycle and the menopause. The importance of the hormonal status in evaluating changes in platelet sensitivity in patients with breast cancer is strongly emphasised.
format Text
id pubmed-1976827
institution National Center for Biotechnology Information
language English
publishDate 1985
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19768272009-09-10 Platelet sensitivity to prostacyclin in normal subjects, and in patients with benign and malignant tumours of the breast. Benedetto, C. Zonca, M. Tavella, A. M. Petitti, E. Massobrio, M. Nigam, S. Slater, T. F. Br J Cancer Research Article Platelet sensitivity to prostacyclin (PG12) was determined in normal male and female subjects, and in patients with benign and malignant tumours of the breast. The IC50 overall mean values for PG12 on ADP-induced platelet aggregation were similar for normal men and women, being 0.97 +/- 0.05 ng ml-1 and 0.83 +/- 0.07 ng ml-1 respectively. However, there were significant differences in the IC50 values for women in the 1st (0.81 +/- 0.06 ng ml-1) vs. 2nd (1.37 +/- 0.13 ng ml-1) phase of the menstrual cycle; post-menopausal women gave similar values to normal males and to pre-menopausal women in the 1st phase of the cycle. No significant differences were found between normal subjects and patients with benign or malignant tumours of the breast when account was taken of the status of the patient in relation to the phase of the menstrual cycle and the menopause. The importance of the hormonal status in evaluating changes in platelet sensitivity in patients with breast cancer is strongly emphasised. Nature Publishing Group 1985-01 /pmc/articles/PMC1976827/ /pubmed/3881119 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Benedetto, C.
Zonca, M.
Tavella, A. M.
Petitti, E.
Massobrio, M.
Nigam, S.
Slater, T. F.
Platelet sensitivity to prostacyclin in normal subjects, and in patients with benign and malignant tumours of the breast.
title Platelet sensitivity to prostacyclin in normal subjects, and in patients with benign and malignant tumours of the breast.
title_full Platelet sensitivity to prostacyclin in normal subjects, and in patients with benign and malignant tumours of the breast.
title_fullStr Platelet sensitivity to prostacyclin in normal subjects, and in patients with benign and malignant tumours of the breast.
title_full_unstemmed Platelet sensitivity to prostacyclin in normal subjects, and in patients with benign and malignant tumours of the breast.
title_short Platelet sensitivity to prostacyclin in normal subjects, and in patients with benign and malignant tumours of the breast.
title_sort platelet sensitivity to prostacyclin in normal subjects, and in patients with benign and malignant tumours of the breast.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976827/
https://www.ncbi.nlm.nih.gov/pubmed/3881119
work_keys_str_mv AT benedettoc plateletsensitivitytoprostacyclininnormalsubjectsandinpatientswithbenignandmalignanttumoursofthebreast
AT zoncam plateletsensitivitytoprostacyclininnormalsubjectsandinpatientswithbenignandmalignanttumoursofthebreast
AT tavellaam plateletsensitivitytoprostacyclininnormalsubjectsandinpatientswithbenignandmalignanttumoursofthebreast
AT petittie plateletsensitivitytoprostacyclininnormalsubjectsandinpatientswithbenignandmalignanttumoursofthebreast
AT massobriom plateletsensitivitytoprostacyclininnormalsubjectsandinpatientswithbenignandmalignanttumoursofthebreast
AT nigams plateletsensitivitytoprostacyclininnormalsubjectsandinpatientswithbenignandmalignanttumoursofthebreast
AT slatertf plateletsensitivitytoprostacyclininnormalsubjectsandinpatientswithbenignandmalignanttumoursofthebreast